Heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-12. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Derived from the seven-residue sequence |
| Molecular weight | About 751.9 g/mol | Average mass; the monoisotopic value is slightly lower |
| Residue count | Seven amino acids | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) | Selank extends tuftsin at the C-terminus |
| Compound class | Synthetic short peptide | Studied in a research setting; not a licensed drug in most markets |
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
== Litigants == The litigants of the case were Robert J. Merena, Charles W. Robinson, Jr., and Glenn Grossenbacher. Robert J. Merena left his job at GlaxoSmithKline in May 1995 and hasn't had a full-time job since. He has said he's had trouble finding another position because employers are wary of hiring a known whistle-blower. Merena, of the Reading, Pa., area, worked as a senior billing-systems analyst at a SmithKline Beecham office in Montgomery County. During his employment at GSK, he passed information to federal investigators working on the case.
The problem of minimizing ET is an NP-hard problem. Even though the class of problems is NP-hard, in practice many instances of protein design can be solved exactly or optimized satisfactorily through heuristic methods.
== Clinical Relevance == MMP-13 has long been a protein of interest in the context of osteoarthritis and rheumatoid arthritis. The role of MMP-13 has also been thoroughly examined in atherosclerosis, specifically in potentially reducing the collagen content of the fibrous cap.
Propranolol is a medication of the beta blocker class. It is used to treat high blood pressure, some types of irregular heart rate, thyrotoxicosis, capillary hemangiomas, akathisia, performance anxiety, and essential tremors, as well as to prevent migraine headaches, and to prevent further heart problems in those with angina or previous heart attacks. It can be taken orally, rectally, or by intravenous injection. The formulation that is taken orally comes in short-acting and long-acting versions. Propranolol appears in the blood after 30 minutes and has a maximum effect between 60 and 90 minutes when taken orally. Common side effects include nausea, abdominal pain, and constipation. It may worsen the symptoms of asthma. Propranolol may cause harmful effects for the fetus if taken during pregnancy; however, its use during breastfeeding is generally considered to be safe. It is a non-selective beta blocker which works by blocking β-adrenergic receptors. Propranolol was patented in 1962 and approved for medical use in 1964. It is on the World Health Organization's List of Essential Medicines. Propranolol is available as a generic medication. In 2023, it was the 69th most commonly prescribed medication in the United States, with more than 9 million prescriptions.
Ridomihan Kersus (リドミハ星人カーサス, Ridomiha Seijin Kāsasu): A plant-themed criminal from Planet Ridomiha who is charged with murder and planetary invasion and is capable of secreting healing liquid from her stalks and producing high-powered water streams capable of slicing objects. Due to their homeworld changing from a water-based planet to a desert-based one, she and her sister Karmia (カーミア, Kāmia) scouted Earth with the intention of stealing its water. After Karmia developed second thoughts, Kersus killed her and framed an alien named Braidy, but Sen-Chan discovers the truth before the Dekarangers delete Kersus with the D-Bazooka. Kersus is voiced by Tomoka Hayashi (林 知花, Hayashi Tomoka), who also portrays her human form. Cuwartlian Dazgonelr (クウォータ星人ダゴネール, Kuwōta Seijin Dagonēru): A childish 10,708-year-old octopus-themed Alienizer from Planet Cuwartl who is charged with turning people into dolls. He manipulates Hikaru, a lonely boy with the power to teleport objects, into helping him before he is deleted by Dekaranger Robo while piloting the Kaijuki Embarns (エンバーンズ, Enbānzu). Dazgonelr is voiced by Yasuhiro Takato (高戸 靖広, Takato Yasuhiro). Zamuzan Sheik (ザムザ星人シェイク, Zamuza Seijin Sheiku): A beetle-themed criminal and bomb manufacturer from Planet Zamuza who was arrested on charges of mass-murder via explosives and imprisoned in the Prison Satellite Prisron (監獄衛生プリズロン, Kangoku Eisei Purizuron).
Sources: en.wikipedia.org
== Products and services == GoodRx started its telemedicine service GoodRx Care in September 2019. It lets people talk to a licensed provider online for common issues and get prescriptions even if they don't have insurance. They also run condition-specific subscription plans that bundle online doctor visits, FDA-approved meds, and home delivery into one monthly payment. On the weight management side, GoodRx offers prescriptions for GLP-1 drugs like semaglutide through their telemedicine platform. This got a boost when the oral version of Wegovy became widely available in the US in early 2026. GoodRx works with drug makers like Novo Nordisk to make some medications (including semaglutide options) more affordable for people paying cash. The telemedicine part took off after GoodRx bought HeyDoctor in 2019 and brought their virtual care tools into the main platform.
== Reactivity == One of the cytochrome P450 isozymes is coded by the gene CYP2B1, where hexobarbital is the substrate. Hexobarbital and the isozyme can form an enzyme-substrate-complex through a hydroxylation reaction, which is involved in the metabolism of xenobiotics. the concentration of hexobarbital also plays a role in oxygenase and oxidase activity of hepatic microsomal cytochrome P450. Triacetyl oleandomycin, an inhibitor for isozyme CYP3A4, also inhibits hexobarbital metabolism and biological activity, indicating a close relationship between hexobarbital and cytochrome P450.
In the late 1920s, Pauling began publishing papers on the nature of the chemical bond. Between 1937 and 1938, he took a position as George Fischer Baker Non-Resident Lecturer in Chemistry at Cornell University. While at Cornell, he delivered a series of nineteen lectures and completed the bulk of his famous textbook The Nature of the Chemical Bond. It is based primarily on his work in this area that he received the Nobel Prize in Chemistry in 1954 "for his research into the nature of the chemical bond and its application to the elucidation of the structure of complex substances". Pauling's book has been considered "chemistry's most influential book of this century and its effective bible". In the 30 years after its first edition was published in 1939, the book was cited more than 16,000 times. Even today, many modern scientific papers and articles in important journals cite this work, more than seventy years after the first publication. Part of Pauling's work on the nature of the chemical bond led to his introduction of the concept of orbital hybridization. While it is normal to think of the electrons in an atom as being described by orbitals of types such as s and p, it turns out that in describing the bonding in molecules, it is better to construct functions that partake of some of the properties of each.
The first Philippine store of Dunkin' Donuts opened in Makati on April 12, 1981 under the Philippine franchisee Golden Donuts Incorporated (GDI). Dunkin' Donuts later expanded outside Metro Manila when Queen City Food Chain, Inc. opened its first outlet in Fuente Osmeña, Cebu City in 1986. It later expanded to Mindanao when its first two branches in Cagayan de Oro opened in 1991. Its first drive-thru store was opened in Tomas Morato Avenue, Quezon City in January 2021. In mid-August 2023, Dunkin' opened its 800th Philippine store in Laoag, becoming the largest coffee operator in the country. On June 1, 2026, Dunkin' opened their 900th Philippine Store Milestone, less than a year after they hit 800th Mark.
Flowers removed from the plant remain alive. Respiration and photosynthesis continue, but no longer have a storehouse of sugars to support them. Additionally, the flowers no longer receive water from the roots, yet transpiration continues. In many countries, cut flowers are a local crop because of their perishable nature. In India, much of the product has a shelf life of only a day. Among these are marigold flowers for garlands and temples, which are typically harvested before dawn, and discarded after use the same day. The postharvest life or vase life of cut flowers can be several days. The vase life of cut flowers and cut greens can be extended with thoughtful care. This care starts from the moment of harvest and continues until they are enjoyed by a flower consumer. Everyone involved must participate in the, "Floral Chain-of-Life", or the life of the cut flowers and cut greens is reduced. Flowers are harvested in the cool part of the day, generally morning, and placed into water as soon as possible to reduce water loss from transpiration. The cut stems go into clean buckets with low pH water as a hydrating solution. Next, the cut stems are refrigerated to slow respiration, photosynthesis and transpiration. Vacuum coolers and hydrocoolers are used for large numbers of flowers on commercial farms. When cold, 2–4 °C (36–39 °F), the cut stems are sized and graded for shipment. Additionally, most or all of the leaves are removed from the cut flower stems to reduce the cost of shipping and reduce disease issues.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.
Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.
No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.